Table 4.
Tumor volume in association with OS
| HR (95% CI) | P-value | |
|---|---|---|
| Total volume (per 100 cm3) | 1.2 (0.9, 1.5) | 0.26 |
| Sex | 0.24 | |
| Male | 1.0 | |
| Female | 1.4 (0.8, 2.3) | |
| Age | 0.65 | |
| ≤59 yrs | 1.0 | |
| 60–69 yrs | 1.2 (0.6, 2.2) | |
| ≥70 yrs | 0.9 (0.4, 1.7) | |
| Primary | 0.72 | |
| Lung adeno | 1.0 | |
| Lung squam | 0.8 (0.4, 1.5) | |
| Lung poorly diff | 1.2 (0.4, 4.0) | |
| Best responsea | <0.001 | |
| PR | 1.0 | |
| SD | 5.6 (1.6, 19.1) | |
| PD | 17.4 (5.1, 59.3) | |
| Metastasizes | 0.008 | |
| M0/M1a | 1.0 | |
| M1b | 1.0 (0.3, 3.1) | |
| M1c | 2.2 (1.3, 4.4) | |
| Previous lines of Tx | 0.001 | |
| 0 | 1.0 | |
| 1 | 2.3 (1.0, 5.3) | |
| 2 or more | 4.4 (1.9, 10.6) | |
| Agent | 0.19 | |
| Pembro | 1.0 | |
| Pembro + other | 0.9 (0.4, 2.3) | |
| Nivo | 1.6 (0.7, 3.5) | |
| On protocol | 0.10 | |
| No | 1.0 | |
| Yes | 0.6 (0.4, 1.1) | |
| Hospitalization w/i 6 wka | <0.001 | |
| No | 1.0 | |
| Yes | 6.0 (3.2, 11.0) | |
| Reason for discontinuationb | – | |
| PD, decline, PD-1 AE | 1.0 | |
| Completed Tx | – | |
| Other | – | |
| Unmeasurable lung | 0.02 | |
| No | 1.0 | |
| Yes | 2.2 (1.0, 4.7) | |
| Unmeasurable LN | 0.74 | |
| No | 1.0 | |
| Yes | 0.9 (0.5, 1.6) | |
| Unmeasurable liver | 0.09 | |
| No | 1.0 | |
| Yes | 1.7 (0.9, 3.3) | |
| Unmeasurable soft tissue | 0.46 | |
| No | 1.0 | |
| Yes | 1.3 (0.7, 2.3) | |
| Lung (per 100 cm3) 2 cm | 1.1 (0.8, 1.4) | 0.54 |
| LN (per 100 cm3) 1.5 cm | 1.1 (0.5, 2.6) | 0.77 |
| Liver (per 100 cm3) 2 cm | 2.8 (1.0, 7.9) | 0.05 |
| Soft tissue (per 100 cm3) 2 cm | 1.3 (0.5, 3.3) | 0.66 |
Notes: aFor those followed for at least weeks; bKruskal–Wallis Test.
Abbreviations: AE, adverse events; SD, stable disease; PD-1, program death-1; PR, partial response; OS, overall survival; LN, lymph node; PD, progression of disease.